Table IV.
Convergent validity between components of the EBDASI, iscorEB, and QOLEB
| Instrument or sub-scores for comparison | Spearman's rho (P-value) | 95% confidence interval |
|---|---|---|
| EBDASI total vs iscorEB total | 0.74 (.002) | 0.37–0.91 |
| EBDASI total vs iscorEB-c | 0.89 (<.001) | 0.68–0.96 |
| EBDASI activity vs iscorEB-c | 0.91 (<.001) | 0.75–0.97 |
| EBDASI damage vs iscorEB-c | 0.90 (<.001) | 0.71–0.97 |
| iscorEB-c vs QOLEB | 0.10 (.711∗) | −0.43–0.59 |
| iscorEB-c vs iscorEB-p | 0.43 (.106∗) | −0.11–0.77 |
| EBDASI total vs QOLEB | 0.09 (.760∗) | −0.45–0.57 |
| EBDASI activity vs QOLEB | 0.10 (.711∗) | −0.43–0.59 |
| EBDASI damage vs QOLEB | 0.06 (.829∗) | −0.47–0.56 |
| EBDASI total vs iscorEB-p | 0.42 (.115∗) | −0.10–0.77 |
| EBDASI activity vs iscorEB-p | 0.46 (.088∗) | −0.07–0.78 |
| EBDASI damage vs iscorEB-p | 0.38 (.165∗) | −0.16–0.75 |
| iscorEB-p vs QOLEB | 0.64 (.01) |
EBDASI, Epidermolysis Bullosa Disease Activity and Scarring Index; iscorEB, Instrument for scoring the clinical outcomes of research for Epidermolysis Bullosa; QOLEB, Quality of Life in Epidermolysis Bullosa.
∗
Not statistically significant.